8-K: Biotricity Inc. Faces Delisting from Nasdaq Capital Market Due to Market Value Deficiency

Biotricity Inc. has received notice of delisting from the Nasdaq Capital Market due to failure to maintain the minimum market value of listed securities, with trading suspended on August 5, 2024.

Summary

• Biotricity Inc. received a delisting notice from the Nasdaq Capital Market on August 1, 2024, due to not meeting the minimum market value of listed securities requirement.
• The company's stock trading was suspended on August 5, 2024.
• The company was initially notified of non-compliance on August 4, 2023, and given until January 29, 2024, to regain compliance.
• An appeal extended the deadline to July 29, 2024, but the company still failed to meet the requirements.
• Nasdaq will file a Form 25 to complete the delisting after appeal periods lapse.
• Biotricity expects its stock to be quoted on the OTC Pink Market under the symbol BTCY.
• The company has applied to the OTCQB for quotation and plans to continue SEC filings.
• Biotricity has 15 days to request a review of the delisting decision.

Sentiment

Score: 3

Explanation: The document indicates a significant negative event with the delisting from Nasdaq, which is likely to negatively impact investor sentiment. The move to the OTC market is a downgrade.

Positives

• Biotricity expects its common stock to be quoted on the OTC Pink Market, ensuring continued trading.
• The company has applied to the OTCQB for quotation, potentially providing a more stable trading platform.
• Biotricity plans to continue filing required periodic reports with the SEC, maintaining transparency.

Negatives

• Biotricity failed to maintain the minimum $35 million market value of listed securities required by Nasdaq.
• The company's stock trading was suspended on the Nasdaq Capital Market.
• The company was unable to regain compliance despite an extended deadline.

Risks

• The delisting from Nasdaq could negatively impact investor confidence and the company's stock price.
• Trading on the OTC Pink Market may result in lower liquidity and higher volatility.
• The company faces the risk of not being approved for quotation on the OTCQB.

Future Outlook

Biotricity expects its common stock to be quoted on the OTC Pink Market and has applied for quotation on the OTCQB. The company plans to continue filing required periodic reports with the SEC.

Management Comments

• The company has submitted an application to the OTCQB for quotation of its common stock.
• The company plans to continue to file its required periodic reports and other filings with the SEC.

Industry Context

Delisting from major exchanges like Nasdaq can be a significant setback for companies, often leading to reduced investor confidence and liquidity. Companies in the biotech sector, like Biotricity, are particularly vulnerable to market fluctuations and regulatory scrutiny, making compliance with listing requirements crucial.

Comparison to Industry Standards

• Many biotech companies face challenges in maintaining market capitalization, especially during periods of market volatility or when clinical trials face setbacks.
• Companies like Geron Corporation and Athersys have faced similar delisting threats due to market capitalization issues, highlighting the common challenges in the biotech sector.
• The move to the OTC market is a common step for companies facing delisting, but it often results in lower trading volumes and increased price volatility compared to major exchanges.

Stakeholder Impact

• Shareholders will likely experience a decrease in the value of their investment due to the delisting.
• Employees may face uncertainty due to the company's financial challenges.
• The company's reputation may be negatively impacted, affecting relationships with customers and suppliers.

Next Steps

• Biotricity will seek quotation on the OTC Pink Market.
• Biotricity will pursue quotation on the OTCQB.
• The company has 15 days to request a review of the delisting decision.
• Nasdaq will file a Form 25 to complete the delisting after appeal periods lapse.

Key Dates

Keywords

delisting, Nasdaq, market value, OTC Pink Market, OTCQB, BTCY, compliance, securities, trading suspension